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ABSTRACT Members of the genus Corynebacterium are increasingly recognized as
pathobionts and can be very resistant to antimicrobial agents. Previous studies have
demonstrated that Corynebacterium striatum can rapidly develop high-level daptomy-
cin resistance (HLDR) (MIC, $256mg/ml). Here, we conducted a multicenter study to
assay for this in vitro phenotype in diverse Corynebacterium species. Corynebacterium
clinical isolates (n=157) from four medical centers were evaluated. MIC values to dap-
tomycin, vancomycin, and telavancin were determined before and after overnight ex-
posure to daptomycin to identify isolates able to rapidly develop daptomycin nonsus-
ceptibility. To investigate assay reproducibility, 18 isolates were evaluated at three
study sites. In addition, the stability of daptomycin nonsusceptibility was tested using
repeated subculture without selective pressure. The impact of different medium
brands was also investigated. Daptomycin nonsusceptibility emerged in 12 of 23 spe-
cies evaluated in this study (C. afermentans, C. amycolatum, C. aurimucosum, C. bovis,
C. jeikeium, C. macginleyi, C. pseudodiphtheriticum, C. resistens, C. simulans, C. striatum,
C. tuberculostearicum, and C. ulcerans) and was detected in 50 of 157 (31.8%) isolates
tested. All isolates displayed low (susceptible) MIC values to vancomycin and telavan-
cin before and after daptomycin exposure. Repeated subculture demonstrated that 2
of 9 isolates (22.2%) exhibiting HLDR reverted to a susceptible phenotype. Of 30 iso-
lates tested on three medium brands, 13 (43.3%) had differences in daptomycin MIC
values between brands. Multiple Corynebacterium species can rapidly develop dapto-
mycin nonsusceptibility, including HLDR, after a short daptomycin exposure period.
KEYWORDS Corynebacterium, daptomycin, nonsusceptible, resistance, telavancin,
vancomycin
C orynebacterium species have historically been considered normal microbiota ofthe skin and mucosal surfaces. Increased use of molecular methods that accurately
identify Corynebacterium to the species level have illuminated species-specific disease
associations and helped to demonstrate the potential of Corynebacterium for causing
invasive infections in immunocompromised patients or biofilm-associated infections in
patients with indwelling hardware (1, 2). Some species, including Corynebacterium
striatum, are noteworthy for multidrug-resistant (MDR) phenotypes. These isolates can
be very challenging to treat when they are the causative agent of infection (3–5).
Daptomycin, a lipopeptide antibiotic, is often considered a drug of “last resort” for
treatment of Gram-positive bacterial pathogens (6), with demonstrated efficacy against
Staphylococcus species, Enterococcus species, and Streptococcus species (7–9). However,
as clinical use of daptomycin increases, antimicrobial nonsusceptibility is reported with
increasing frequency (10–12).
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In previous reports by our group and others, clinical isolates of C. striatum have
been observed to rapidly develop high-level daptomycin resistance in vivo (HLDR;
MIC values of $256mg/ml) (13–16). These findings have been recapitulated in vitro
with experiments exposing C. striatum isolates to daptomycin, in which all isolates
evaluated were observed to have the HLDR phenotype (17). The mechanism of
HLDR in C. striatum has recently been elucidated to occur via loss-of-function muta-
tions in pgsA2, encoding an essential enzyme for phosphatidylglycerol (PG) synthe-
sis (18). Mutations in pgsA2 have also been attributed to HLDR phenotypes in
Staphylococcus aureus, Enterococcus faecalis, and multiple species in the viridans
group streptococci (11, 19, 20).
While the findings of prior studies suggest that daptomycin may not be an optimal
therapy for infections with C. striatum, it remains unclear if other Corynebacterium spe-
cies are as likely to develop daptomycin nonsusceptibility. The objectives of our cur-
rent multicenter study were to evaluate other clinically relevant isolates in the
Corynebacterium genus for rapid emergence of daptomycin nonsusceptibility, includ-
ing HLDR, and to expand the investigation of C. striatum clinical isolates to multiple ge-
ographic regions in the United States.
MATERIALS ANDMETHODS
Isolate cohort. Isolates of Corynebacterium were collected both prospectively and retrospectively
from the following four medical centers: Washington University/Barnes-Jewish Hospital (WU; St. Louis,
MO), NorthShore University HealthSystem (NS; Evanston, IL), Weill Cornell Medical Center/NewYork-
Presbyterian Hospital (WC; New York City, NY), and Hospital for Special Surgery (HSS; New York City, NY).
Isolates were recovered from a variety of clinical specimen types following standard operating proce-
dures at each study site as part of routine patient care. Isolates were included if they were clinically
reported to the species level at the study site per the laboratory standard operating procedure, i.e., were
deemed clinically relevant in the corresponding culture type. All isolates were sent to WU for characteri-
zation. A subset of isolates was later sent to NS and WC for reproducibility testing. Prior to susceptibility
testing, each isolate was subcultured two times by the performing laboratory without selective pressure.
Organism identification. Upon arrival at WU, the identification of each study isolate was confirmed
using two matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS)
platforms (MALDI Biotyper [Bruker Daltonics, Inc., Billerica, MA]; Compass Library MBT 8468 MSP and
Vitek MS [bioMérieux, Inc., Durham, NC]; Knowledge Base version 3.0). Isolates were assigned a study
identifier (see Table S1 in the supplemental material) with the format COR###-A; following overnight ex-
posure to daptomycin, any daptomycin nonsusceptible isolates were archived with the format COR###-
B. One isolate, COR158-A, was identified at WC as C. pyruviciproducens using 16S rRNA gene sequencing
(21).
Antimicrobial susceptibility testing. Antimicrobial susceptibility testing was performed using gra-
dient diffusion with Etest for daptomycin and vancomycin, (bioMérieux, Inc.) and MTC MIC test strip for
telavancin (Liofilchem, Inc., Waltham, MA). Isolates were tested on Mueller-Hinton agar with 5% sheep
blood (MH1B) (Hardy Diagnostics, Santa Maria, CA) and incubated at 35°C in air following Clinical and
Laboratory Standards Institute (CLSI) interpretive criteria (22). MIC results were recorded at 24 h and 48
h of incubation, and the 48-h time point data are reported as the MIC. Quality control testing using
Streptococcus pneumoniae ATCC 49619 and Staphylococcus aureus ATCC 29213 was performed each day
of testing and assessed using CLSI criteria.
Corynebacterium-HLDR assay. An in vitro assay was used to investigate the rapid development of
daptomycin nonsusceptibility as previously described (13, 17). Briefly, following organism identification
and baseline susceptibility testing, each isolate was inoculated into tryptic soy broth (Becton, Dickinson
and Company, Franklin Lakes, NJ) to generate a suspension equivalent to a 0.5 McFarland standard. Two
tubes containing 5ml each were inoculated per isolate, one containing a daptomycin Etest strip cut in
half with both halves submerged below the level of the broth as a source of daptomycin for the assay
and one as a growth control without the daptomycin Etest strip (Fig. 1). The tubes were incubated over-
night at 35°C in air with agitation on a shaker. Following incubation, isolates were tested for susceptibil-
ity to daptomycin, vancomycin, and telavancin using gradient diffusion assays.
Reproducibility of the daptomycin resistance phenotype at multiple study sites. A subset of 18
Corynebacterium isolates was sent from WU to NS and WC for testing with the Corynebacterium HLDR
assay described above. Recipients of these isolates were blinded to the organism identification and dap-
tomycin susceptibility status as initially determined at WU.
Stability of the daptomycin resistance phenotype. To investigate the stability of daptomycin non-
susceptibility, nine nonsusceptible isolates (including C. macginleyi, C. ulcerans, C. aurimucosum, C. simu-
lans, C. jeikeium, C. amycolatum, and C. afermentans) were serially subcultured on 5% sheep blood agar
and incubated at 35°C in air without selective pressure as previously described (13). Briefly, isolates were
subcultured from a single colony for 10 consecutive days (or until reversion to daptomycin susceptibility
was observed), and daptomycin MIC testing was performed.
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Impact of MH+B medium brand on daptomycin resistance phenotype. To measure the impact
of the MH1B medium brand on the Corynebacterium HLDR assay described above, we performed test-
ing on 30 isolates (15 C. striatum and 15 non-C. striatum) using two additional brands of MH1B (Remel
[Thermo Fisher Scientific, Lenexa, KS] and BBL [Becton, Dickinson and Company]) in parallel with media
from Hardy Diagnostics.
RESULTS
A total of 163 clinical isolates were collected for this study. Of these, 86 origi-
nated from WU, 24 from NS, 51 from WC, and 2 from HSS. Five isolates were omitted
from the study; two were nonviable for subculture from the freezer stock tubes,
two had a final organism identification of Turicella otitidis, and one isolate (COR082-
A) was a duplicate of another isolate from the same patient. This brought the final
sample size to 158 (n = 39 C. striatum, n = 119 non-C. striatum). Isolates were derived
from a variety of specimen types, with the three most common being respiratory
(n = 39, including bronchoalveolar lavage fluid, bronchial washing fluid, sputum,
tracheal aspirate, pleural fluid, and nasal wounds), blood (n = 24), and ventricular
assist device driveline wounds (n = 18) (Table S1). One isolate of C. amycolatum
(originating from a driveline wound, isolated at WU), was observed to have HLDR at
baseline antimicrobial susceptibility testing; all other isolates were initially suscepti-
ble to daptomycin (Fig. 2).
Following subculture and confirmation of organism identification, all isolates
were tested for overnight development of daptomycin nonsusceptibility (Table 1,
Fig. 2). After daptomycin exposure, 50 of 158 (31.6%) isolates exhibited a nonsus-
ceptible phenotype to daptomycin (susceptible breakpoint, #1.0mg/ml) (Fig. 3B)
(22). Nine of these isolates demonstrated a heterogeneous phenotype with a subset
of colonies with elevated MIC values (Fig. 3C). The colonies of the subset were rei-
dentified using MALDI-TOF MS to exclude the possibility of a mixed or contami-
nated culture.
For C. striatum, 35 of 39 (89.7%) isolates displayed visible turbidity after overnight
growth in broth with daptomycin. Following antimicrobial susceptibility testing of
these 35 isolates, 32 displayed HLDR (daptomycin MIC value, $256mg/ml) and 3
remained susceptible to daptomycin (Fig. 2B). Of the 119 non-C. striatum isolates, 47
developed visibly turbid cultures after daptomycin exposure, and subsequent testing
showed that 18 of the 47 isolates that resulted in turbid cultures were nonsusceptible
to daptomycin for an overall nonsusceptibility rate of 15.1% (18/119). MIC values
FIG 1 Examples of isolates incubated in broth overnight with and without exposure to daptomycin.
Isolate 1 was rated as not visibly turbid following overnight incubation and therefore was deemed
susceptible to daptomycin. Isolate 2 was rated as turbid, prompting susceptibility testing of the
isolate for daptomycin, vancomycin, and telavancin.
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following overnight exposure ranged from 2.0 to $256mg/ml, with 14 of these being
HLDR (Fig. 2C).
All isolates were also assayed for MICs to vancomycin and telavancin (before and af-
ter overnight daptomycin exposure. All 158 isolates displayed low vancomycin (suscep-
tible) and telavancin MIC values at baseline and maintained these low MIC values after
daptomycin exposure (Fig. 4). Of note, there are no established breakpoints available
for telavancin with Corynebacterium species; however, the highest MIC value observed
was 0.25mg/ml before daptomycin exposure, with a range of 0.016 to 0.125mg/ml af-
ter daptomycin exposure, implying telavancin susceptibility before and after daptomy-
cin exposure.
To investigate the stability of the daptomycin-nonsusceptible phenotype in non-C.
striatum species, nine isolates that had been found to develop daptomycin nonsus-
ceptibility were randomly selected and subcultured 10 times without selective pressure
(Table 2). Two isolates were found to lose the HLDR phenotype after repeated passag-
ing; COR007-B (C. macginleyi) had an initial daptomycin MIC value of $256mg/ml and
had an MIC value of 0.064mg/ml after seven passages; COR069-B (C. jeikeium) also
started with a daptomycin MIC value of $256mg/ml and had an MIC value of 1.0mg/
ml after five passages (Fig. 5). Of note, COR069-A (the parent strain for COR069-B) had
expressed a resistant subpopulation during initial testing: the majority of the growth
had a daptomycin MIC value of 1.0mg/ml, but a resistant subpopulation of colonies
had an MIC value of $256mg/ml.
To investigate the reproducibility of our HLDR findings, 18 isolates were tested at
WU, NS, and WC for the development of daptomycin nonsusceptibility. Initially 12
(66.7%) yielded the same phenotype at all three sites (Table 3; trial 1). As part of the
investigation for discrepant results, we hypothesized that each study site may have
regarded the growth in broth differently, i.e., evaluation of turbidity and the decision
to perform susceptibility testing after daptomycin exposure. To address this, repeat
FIG 2 Clinical Corynebacterium isolates rapidly developed resistance to daptomycin following overnight exposure. (A) Summary table of daptomycin MIC
values. (B and C) Bar charts represent the number of isolates for (B) C. striatum and (C) non-C. striatum isolates with daptomycin MIC values before and
after overnight daptomycin exposure. The dashed line indicates the susceptible breakpoint for daptomycin (#1.0mg/ml is susceptible).
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testing was performed and included follow-up susceptibility testing regardless of an
isolate’s turbidity in broth (Table 3; trial 2). This yielded congruent results between all
three study sites for 15 of the 18 (83.3%) isolates.
We further hypothesized that differences in medium brand for MH1B agar may have
accounted for differences in observed phenotype; WU used Hardy media, while NS and WC
both used BBL. To investigate the possible impact of medium brand on the expression of a
rapidly developing daptomycin-nonsusceptible phenotype, 30 isolates (15 C. striatum, 15
non-C. striatum) were tested at WU on all three types of commercially available MH1B agar
(Hardy, BBL, and Remel). This evaluation included the 6 isolates that were initially found to
be discrepant during reproducibility testing at the three study sites. Of the 30 isolates, 13
(43.3%) were found to have some difference in their daptomycin susceptibility phenotype
between the three medium brands (2 C. striatum and 11 non-C. striatum) (Tables 4
and 5). These differences involved either a frank change from susceptible to nonsus-
ceptible status or a situation in which a nonsusceptible subpopulation of colonies in
the zone of growth inhibition was observed only on certain medium brands (Fig. 6).
Of note, the three isolates with discrepant results between study sites during repro-
ducibility testing (COR069-A, COR109-A, and COR147-A) each retained their pheno-
types when tested on the three medium brands.
DISCUSSION
Corynebacterium bacteria have traditionally been regarded as largely commensal
organisms, but members of this genus are pathogens and pathobionts. Some species
are associated with distinct clinical presentations (e.g., C. macginleyi and ocular infec-
tions), while others, including C. striatum, are associated with device-associated infec-
tions and MDR (1–4). Daptomycin, a lipopeptide antibiotic, initially showed great
promise as a therapeutic option for C. striatum infections. However, studies from our
group and others demonstrated the rapid emergence of daptomycin resistance in
TABLE 1 Clinical isolates of Corynebacterium and their daptomycin susceptibility status
before and after in vitro exposure to daptomycin
Corynebacterium sp.
No. of isolates by











C. accolens 1 (0, 0, 1, 0) 0 0
C. afermentans 3 (3, 0, 0, 0) 0 1a (1)
C. amycolatum 42 (31, 3, 8, 0) 1 1
C. aurimucosum 3 (1, 2, 0, 0) 0 2
C. bovis 3 (0, 0, 3, 0) 0 1a (1)
C. coyleae 1 (1, 0, 0, 0) 0 0
C. diphtheriae 2 (2, 0, 0, 0) 0 0
C. imitans 1 (1, 0, 0, 0) 0 0
C. jeikeium 13 (9, 0, 3, 1) 0 4a (4)
C. kroppenstedtii 3 (2, 0, 1, 0) 0 0
Corynebacterium lipophile group 1 (0, 1, 0, 0) 0 0
C. lipophiloflavum 1 (0, 1, 0, 0) 0 0
C. macginleyi 6 (5, 0, 1, 0) 0 4a (1)
C. mucifaciens 1 (1, 0, 0, 0) 0 0
C. propinquum 7 (0, 3, 4, 0) 0 0
C. pseudodiphtheriticum 12 (4, 2, 6, 0) 0 1
C. pyruviciproducens 1 (0, 0, 1, 0) 0 0
C. resistens 1 (0, 0, 1, 0) 0 1
C. simulans 1 (0, 1, 0, 0) 0 1
C. striatum 39 (8, 10, 20, 1) 0 32a (1)
C. tuberculostearicum 9 (9, 0, 0, 0) 0 1a (1)
C. ulcerans 3 (3, 0, 0, 0) 0 1
C. urealyticum 3 (2, 1, 0, 0) 0 0
aOne or more isolates exhibited a nonsusceptible subpopulation; the values in parentheses indicate the number
of isolates with this phenotype. WU, Washington University/Barnes Jewish Hospital; NS, NorthShore University
HealthSystem; WC, Weill Cornell Medical Center/NewYork-Presbyterian Hospital; HSS, Hospital for Special
Surgery.
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this species (13, 14, 16, 17). While there are limited data available for non-C. striatum
isolates, two case reports described daptomycin-resistant isolates of C. jeikeium and
C. propinquum from a bloodstream infection and a case of prosthetic valve endocar-
ditis, respectively (23, 24). In both cases, the patients had been treated with dapto-
mycin prior to antimicrobial susceptibility testing. Here, we aimed to expand upon
these investigations by testing a diverse group of clinically relevant Corynebacterium
species isolates as well as additional C. striatum clinical isolates from multiple geo-
graphic sites.
After exposing 158 clinical Corynebacterium isolates to daptomycin overnight, we
observed the rapid development of daptomycin resistance in 50 (31.6%) isolates (32
C. striatum and 18 non-C. striatum). The majority of these developed the phenotype
previously referred to as HLDR, i.e., isolates with a daptomycin MIC value of
$256mg/ml (18). However, among 4 non-C. striatum isolates, we observed a MIC
value that was lower but still above the CLSI breakpoint for susceptibility to dapto-
mycin. In addition, 9 isolates (1 C. striatum and 8 non-C. striatum) expressed a subset
of colonies with HLDR (which was officially interpreted as a MIC of $256mg/ml), but
the majority of the population was susceptible to daptomycin (Fig. 3C). Further, the
repeated subculture of several isolates (including one that had initially expressed a
resistant subpopulation) without selective pressure indicated a potential for com-
plete reversal of HLDR among certain non-C. striatum isolates. Of note, one isolate of
C. amycolatum (COR081-A) from a driveline wound had a baseline MIC value of
$256mg/ml; medical chart review revealed that this patient had been treated for
6 weeks with daptomycin.
Collectively, these results differ from our group’s previous observations of uni-
form, stable HLDR among C. striatum isolates in vitro as evaluated with standardized
antimicrobial susceptibility testing (13, 17). Interestingly, during our prior trials of
the Corynebacterium-HLDR assay with C. striatum, a lag was observed during growth
in broth with daptomycin at 4 h of incubation compared to controls (although no
lag was discernible by 24 h) (13). We hypothesized that this could be due to the
FIG 3 (A to C) Examples of non-C. striatum isolates with (A) uniform susceptibility (MIC, 0.25mg/ml), (B) uniform nonsusceptibility (MIC, $256mg/ml), and
(C) a nonsusceptible subpopulation of colonies to daptomycin (MIC, $256mg/ml). Plates represent MIC testing of isolates following their overnight
exposure to daptomycin.
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presence of a heteroresistant population, which was selected in the presence of
daptomycin. In a study by another group, a clinical isolate of C. striatum originating
from a case of native valve endocarditis was reported to exhibit two subpopulations
upon testing with daptomycin—one with a MIC value of $256mg/ml and one with
a MIC value of 0.094mg/ml (15). Together with our current study, these findings sug-
gest that, for at least some isolates, both C. striatum and other Corynebacterium
species may demonstrate a mixed resistance phenotype following exposure to
daptomycin.
The structural similarities between daptomycin (a lipopeptide) and telavancin (a
lipoglycopeptide) prompted us to investigate the impact of daptomycin exposure to
telavancin as well as vancomycin (a glycopeptide). Our entire isolate cohort was sus-
ceptible to both vancomycin and telavancin, both before and after exposure to dap-
tomycin. These results are congruent with our previous large study of C. striatum iso-
FIG 4 All Corynebacterium isolates exhibited low MIC values to vancomycin (susceptible) and telavancin (indicative of susceptibility) before and after
daptomycin exposure. (A) Summary table of vancomycin and telavancin MIC values. (A and B) Bar charts represent the number of isolates tested for (B)
vancomycin and (C) telavancin before and after overnight daptomycin exposure. The dashed line indicates the susceptible breakpoint for vancomycin
(MIC,# 8.0mg/ml). There are no telavancin breakpoints available for Corynebacterium species.








COR007-Ba C. macginleyi $256 0.064
COR013-B C. macginleyi $256 $256
COR016-B C. ulcerans $256 $256
COR057-B C. aurimucosum 16.0 16.0
COR060-B C. simulans $256 $256
COR069-Ba C. jeikeium $256 1.0
COR081-B C. amycolatum $256 $256
COR103-B C. aurimucosum $256 $256
COR109-B C. afermentans 2.0 2.0
aIsolates COR007-B and COR069-B were subcultured for 7 and 5days, respectively.
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lates (17). The notion that exposure to one of these agents can potentially lead to re-
sistance to a second drug has been demonstrated using S. aureus, in which vancomy-
cin induces resistance to daptomycin, presumably through cell wall thickening
(25–28). In many studies, isolates were derived from daptomycin-naive patients. The
impact of vancomycin exposure on daptomycin susceptibility represents an interest-
ing area of future study with Corynebacterium.
The Corynebacterium HLDR assay conducted throughout this study represents a
potential workflow for clinical laboratories to assess for rapid development of dapto-
mycin resistance in Corynebacterium isolates. Thus, a large portion of our study aimed
FIG 5 Instability of the daptomycin nonsusceptibility phenotype in an isolate of C. macginleyi (COR069-B). Following repeated subculture without selective
pressure, the MIC values to daptomycin were tested. (A to D) Representative images are shown for subcultures 1 (A), 2 (B), 3 (C), and 4 (D). Additional
subculturing was performed for days 5 to 10 but yielded a single population with an MIC value of 1.0mg/ml, i.e., susceptible (no resistant subpopulation
was noted).
TABLE 3 Reproducibility of Corynebacterium HLDR testing at three study sitesa
Study
identifier Corynebacterium sp.
Data for WU (Hardy MH+B)
(mg/ml)
Data for NS (BBL MH+B)
(mg/ml)








Trial 1 Trial 2 Trial 1 Trial 2 Trial 1 Trial 2
Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post
COR019-A C. striatum 0.064 $256 0.125 $256 0.125 NA 0.125 $256 0.064 $256 0.064 $256 2 3
COR025-A C. striatum 0.064 $256 0.125 $256 0.064 $256 3 3
COR032-A C. propinquum 0.032 0.032 0.064 0.032 0.064 NA 3 3
COR033-A C. amycolatum 0.064 NA 0.064 NA 0.032 NA 3 3
COR036-A C. pseudodiphtheriticum 0.064 NA 0.125 NA 0.125 NA 3 3
COR057-A C. aurimucosum 0.032 32.0 0.032 8.0 0.032 8.0 3 3
COR060-A C. simulans 0.125 $256 0.25 $256 0.125 NA 0.125 $256 0.25 NA 0.125 $256 2 3
COR062-A C. urealyticum 0.125 0.5 0.125 0.064 0.125 0.125 3 3
COR069-A C. jeikeium 0.50 $256 0.50 $256 0.25 0.032 0.5 0.25 0.50 0.25 0.25 NA 2 2
COR071-A C. jeikeium 1.0 1.0 1.0 4.0 1.0 1.0 3 3
COR081-A C. amycolatum $256 $256 $256 $256 192 $256 3 3
COR103-A C. aurimucosum #0.016 16.0 0.032 $256 0.032 8.0 0.032 8.0 ,0.016 NA #0.016 16.0 2 3
COR109-A C. afermentans 0.5 $256 0.25 $256 0.125 2.0 0.25 $256 0.25 NA 0.25 NA 2 2
COR111-A C. amycolatum 0.064 NA 0.125 NA 0.125 NA 3 3
COR122-A C. pseudodiphtheriticum 0.032 NA 0.0625 NA 0.032 NA 3 3
COR129-A C. striatum 0.25 $256 0.125 $256 0.125 $256 3 3
COR147-A C. striatum 0.125 0.064 0.064 0.064 0.125 $256 0.125 $256 0.125 $256 0.125 $256 2 2
COR151-A C. kroppenstedtii 0.50 NA 0.25 NA 0.50 NA 3 3
a“Pre” and “Post” refer to daptomycin MIC values (mg/ml) at baseline and after overnight exposure to daptomycin, respectively. For isolates marked “NA,” no turbidity was
observed following growth in broth with daptomycin; therefore, postexposure testing was not performed. WU, Washington University/Barnes Jewish Hospital; NS,
NorthShore University HealthSystem; WC, Weill Cornell Medical Center/NewYork-Presbyterian Hospital; HSS, Hospital for Special Surgery; BBL, Becton, Dickinson and
Company.
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to investigate how prevalent daptomycin nonsusceptibility was in a diverse group of
Corynebacterium clinical isolates and the reproducibility of results when this assay was
performed at different study sites. Initially, our results were only 66% in agreement,
prompting discussion among the three sites about the details of experimentation. We
realized that variability may have been introduced due to the subjective nature of
assessing the turbidity of isolates grown in broth with daptomycin; i.e., one site may
have set up post-daptomycin exposure MIC testing, while others did not. This could be
especially difficult to gauge for lipophilic non-C. striatum Corynebacterium species, as
the isolates evaluated in the experiments did not always have robust growth, even in
broth control tubes. When repeat testing was performed for discrepant isolates in
which all broths were set up post-daptomycin exposure, results were 83.3% in agree-
ment. This discrepancy could be mitigated in a laboratory workflow by requiring post-
TABLE 4 Testing for overnight daptomycin nonsusceptibility with three different medium brands of MH1B agara
Study ID Corynebacterium sp.
BBL Hardy Remel No. of medium types
with phenotype
agreementPre Post Pre Post Pre Post
COR006-A C. tuberculostearicum 0.125 $256 (0.125) 0.25 $256 (0.25) 0.032 $256 (0.125) 3
COR007-A C. macginleyi 0.125 0.064 0.125 $256 0.125 $256 (0.064) 0
COR013-A C. macginleyi 0.125 $256 (0.032) 0.125 $256 (0.064) 0.064 $256 (0.032) 3
COR016-A C. ulcerans 0.125 $256 (0.125) 0.125 4 (0.064) 0.125 32 (0.032) 3
COR019-A C. striatum 0.125 $256 0.125 $256 0.125 $256 3
COR023-A C. jeikeium 0.25 8 0.25 2 0.125 0.5 2
COR024-A C. ulcerans 0.25 0.25 0.5 2 0.50 0.5 2
COR025-A C. striatum 0.125 $256 0.25 $256 0.064 $256 3
COR030-A C. striatum 0.064 $256 0.125 $256 0.032 $256 3
COR031-A C. striatum 0.032 $256 0.125 $256 0.125 $256 3
COR037-A C. striatum 0.125 $256 0.125 $256 0.125 $256 3
COR040-A C. bovis 0.25 0.5 0.25 2 0.125 0.5 2
COR044-A C. striatum 0.125 $256 (4) 0.125 $256 (4) 0.064 $256 (4) 3
COR046-A C. striatum 0.125 $256 0.032 $256 0.032 $256 3
COR049-A C. striatum 0.25 $256 0.25 $256 0.125 $256 3
COR057-A C. aurimucosum #0.016 128 (32) 0.064 128 0.032 $256 (16) 2
COR060-A C. simulans 0.25 $256 (0.064) 0.25 $256 0.125 $256 2
COR063-A C. jeikeium 0.25 0.25 0.032 $256 (0.064) 0.25 0.032 2
COR067-A C. jeikeium 0.50 1 0.5 6 0.25 1 2
COR069-A C. jeikeium 0.50 0.25 0.50 $256 0.25 $256 2
COR081-A C. amycolatum 64 $256 $256 $256 $256 $256 3
COR103-A C. aurimucosum #0.016 32 0.032 $256 #0.016 $256 (64) 0
COR109-A C. afermentans 0.25 $256 (0.25) 0.25 $256 0.25 $256 (0.125) 2
COR128-A C. striatum 0.032 $256 0.50 $256 0.25 $256 3
COR129-A C. striatum 0.25 0.125 0.25 0.125 0.25 0.25 3
COR134-A C. striatum 0.125 $256 0.125 $256 0.064 $256 3
COR138-A C. striatum 0.125 $256 0.125 $256 0.064 $256 3
COR141-A C. striatum 0.25 $256 0.125 $256 (0.5) 0.25 $256 2
COR147-A C. striatum 0.032 $256 0.064 0.064 0.064 #0.016 2
COR163-A C. striatum 0.125 $256 0.125 $256 0.25 $256 3
a“Pre” and “Post” refer to daptomycin MIC values (mg/ml) at baseline and after overnight exposure to daptomycin, respectively. Values in parentheses indicate the MIC
values observed for a subpopulation of colonies. Phenotype agreement refers to the susceptibility interpretation and/or observation of a nonsusceptible subpopulation, if
applicable.
TABLE 5 Testing for overnight daptomycin nonsusceptibility with three different medium
brands of MH1B agara
MIC summary statistics
BBL Hardy Remel
Pre Post Pre Post Pre Post
Median 0.125 $256 0.125 $256 0.125 $256
Mode 0.125 $256 0.125 $256 0.125 $256
Minimum #0.016 0.064 0.032 0.064 #0.016 #0.016
Maximum 64 $256 $256 $256 $256 $256
a“Pre” and “Post” refer to daptomycin MIC values (mg/ml) at baseline and after overnight exposure to
daptomycin, respectively.
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daptomycin exposure testing for non-C. striatum Corynebacterium isolates, regardless
of visible turbidity.
The discussion among study sites also revealed that two different brands of
MH1B had been utilized for antimicrobial susceptibility testing, leading us to test
three commercially available brands of MH1B media in parallel at a single site.
When a subset of isolates was tested at a single site on the different medium brands,
43.4% of isolates gave different results. In addition, the remaining three discrepant
results from intersite reproducibility testing were explained by the observed pheno-
type differences of the three medium brands. There was no clear trend between me-
dium type and observed daptomycin nonsusceptibility phenotype, including the
expression of nonsusceptibility. While the major components of MHB agar are the
same between the three medium brands, our findings could be explained by subtle
differences in medium lipid composition, blood source, or other manufacturing dif-
ferences (29).
We observed an unstable daptomycin-nonsusceptible phenotype for two non-C.
striatum isolates, which differs from our previous findings with C. striatum. This
raises the possibility that there could be differences in the mechanism(s) leading to
daptomycin resistance between C. striatum and non-C. striatum species. An inter-
esting area of future study could employ lipidomics to investigate differences in the
membrane phosphatidylglycerol (PG) composition of non-C. striatum Corynebacterium
species; previous studies from our group used this approach to demonstrate that
PG content is greatly reduced in HLDR strains of C. striatum (18). Characterization of
PG content in other species could help explain the differences in phenotypes we
observed between the majority of C. striatum and non-C. striatum species. Also,
subtle differences in the number of subcultures from frozen stocks may have
impacted the observed differences in phenotypes between study sites; each isolate
was subcultured an additional time at WU prior to being sent to the other two
study sites.
Our study has several limitations, including evaluation of isolates that were initially
recovered from the respiratory tract (39 of 155, or 25.2%). We acknowledge that dapto-
mycin is not used in the treatment of pneumonia; however, these isolates were
included in our study, as they represent important causes of infection and have the
FIG 6 Example of daptomycin-nonsusceptible phenotype variability during testing on three commercially available brands of Mueller-Hinton with blood
agar. (A to C) An isolate of C. simulans (COR060-A) was exposed to daptomycin in broth overnight and then tested for daptomycin MIC values on the
following three different medium brands: (A) BBL, (B) Hardy, and (C) Remel. A resistant subpopulation of colonies was only observed when tested on BBL
medium.
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potential for progression to disseminated disease beyond the respiratory tract. An
additional study limitation is posed by the rarity of certain species (several species had
only a single representative isolate); therefore, our findings from these species may not
translate to other isolates of these species.
The strengths of our study are the inclusion of many Corynebacterium clinical iso-
lates collected from multiple study sites over several years, representing many clinically
relevant species. An additional strength is the inclusion of isolates collected both retro-
spectively and prospectively.
Together, our findings suggest that multiple Corynebacterium species, in addition to
C. striatum, are able to rapidly develop resistance to daptomycin. This has important
clinical implications, especially for conditions where daptomycin may be used for long-
term treatment of Corynebacterium infections.
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